FDA Releases Updated Pyrogen and Endotoxin Testing Guidance (2nd Edition, March 2026)
On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued the second edition of the Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers, delivering updated, practice-oriented regulatory compliance direction for the pharmaceutical, biological product, and medical device industries. This revision refines sampling frameworks, out-of-specification (OOS) result management, sample pooling rules, and alternative method adoption, emphasizing risk-based scientific decision-making and dynamic quality oversight.
Image Source: https://www.cnbc.com/2020/03/10/fda-suspends-foreign-food-and-drug-inspections-over-coronavirus-outbreak.html
Key Updates in Sampling and Process Control
The updated guidance promotes a flexible, risk-based sampling strategy rather than rigid, one-size-fits-all protocols. Manufacturers are advised to start with broad sampling coverage and gradually refine to targeted monitoring as process understanding improves. Any adjustments to sampling plans must be documented and updated in regulatory filings accordingly.
Critical attention is also placed on sample storage and handling. Firms are required to justify sample stability through experimental data, verifying that endotoxin detectability remains consistent under defined storage and pre-treatment conditions.
Clarified Retesting Rules for Endotoxin Assays
FDA clearly defines scenarios where retesting is permissible:
If an initial test failure occurs below the Maximum Valid Dilution (MVD), retesting at a higher dilution (not exceeding MVD) is allowed.
If an OOS result occurs at the MVD and is not attributable to operational error, the batch must be rejected.
All retesting conditions must be pre-defined in approved standard operating procedures (SOPs).
Limited Approval for Finished Product Sample Pooling
A notable regulatory breakthrough is the controlled allowance of sample pooling for finished products:
Pooling up to three equivalent units is permitted for small-volume parenterals (≤100 mL) and medical device extracts.
MVD must be proportionally reduced (divided by the number of pooled units) to avoid false negatives caused by dilution.
Pooling is prohibited for suspensions, products with inherently low initial MVD, and in-process samples from different manufacturing stages.
To preserve traceability, FDA recommends aseptically collecting aliquots from fully mixed containers, keeping original units available for potential follow-up testing if pooled samples fail.
Encouragement for Validated Alternative Test Methods
The guidance supports the use of non-compendial alternative assays—such as the Monocyte Activation Test (MAT)—when fully validated per USP General Chapter <1225> to show equivalent or better performance than compendial methods.
In cases of conflicting results or regulatory disputes, the USP gel-clot method remains the arbitral standard.
Phase-Out of Outdated Limit Tables and Integration of QbD
FDA has withdrawn the fixed endotoxin limit table from the 1987 guidance, now requiring limits to be calculated using formulas in USP or AAMI standards.
The document deeply integrates Quality by Design (QbD) principles:
Endotoxin control strategies should be built on product and process understanding.
Quantitative trending analysis is encouraged to detect deviations early and prevent batch failure.
In-process limits should align with finished-product release specifications.
Other Important Clarifications
Rabbit Pyrogen Test (USP <151>): Remains required for certain biological products and may be necessary if non-endotoxin pyrogens are a risk or assay interferences cannot be resolved.
Medical Device Endotoxin Limits: Aligned with USP <161>, with specified thresholds (e.g., 0.5 EU/mL for cardiovascular devices, 0.06 EU/mL for cerebrospinal fluid-contacting devices).
Veterinary Products: Endotoxin limits should be based on the highest dose for the smallest target species.
Control Standard Endotoxins (CSEs): Still acceptable if calibrated and traceable to international reference standards.
Conclusion
The 2026 second edition of FDA’s Pyrogen and Endotoxins Testing guidance modernizes regulatory expectations by balancing scientific flexibility with strict quality safeguards. Manufacturers should promptly update SOPs, validate methods, adjust sampling and pooling practices, and ensure compliance with the revised requirements for market approval and post-market surveillance.